Protara Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing therapies for cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy based on the immunopotentiator OK-432, which is currently approved in Japan and Taiwan for lymphatic malformations and multiple oncologic indications. Protara holds worldwide rights to TARA-002 excluding Japan and Taiwan and is evaluating it for non-muscle invasive bladder cancer (NMIBC) and lymphatic malformations in the United States. The company is conducting the Phase 2 ADVANCED-2 trial for NMIBC and plans to initiate the ADVANCED-3 trial. Its second program is IV Choline Chloride, an investigational phospholipid substrate replacement therapy for patients receiving parenteral support, which has the potential to become the first FDA-approved IV choline formulation for this population. Protara was founded on the principle of applying modern scientific and regulatory advancements to established mechanisms to create new development opportunities.

Summarised from the company's own disclosures, fiscal year ended Mar 2026

Industry Biotechnology Homepage protaratx.com
Sector Healthcare IR page ir.protaratx.com
Tags
cell therapy, immunopotentiator, non-muscle invasive bladder cancer, lymphatic malformations, parenteral support, choline chloride, oncology, rare diseases, TARA-002, OK-432, Picibanil, IV Choline Chloride, Chugai Pharmaceutical
Press page —

Metrics

Valuation  
Market cap $ 182.901M
Market cap (USD) $ 182.901M
P/E -2.16
PEG —
P/BV 1.30
P/S 62.04
P/OCF -2.54
P/FCF -3.24
Dividend yield —
Turnover / mcap —
Returns  
ROE -31.6%
ROI -38.6%
ROIC -32.5%
Profit margin —
Growth  
Revenue growing —
Profits growing No
Revenue up 3y —
Revenue up 5y —
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable No
Margin expanding —
Buying back stock No
Diluting (TTM) Yes
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 36
Quality score -75.0%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013
Revenue — — — — — — — — — — — 2.948M —
Net profit -57.439M -44.596M -40.42M -65.952M -47.252M -33.978M -14.992M -20.729M -29.964M -28.526M -21.377M -3.342M -7.912M
Free cash flow -56.459M -35.871M -37.602M -26.577M -35.098M -24.291M -15.662M -23.352M -22.387M -23.958M -17.764M -10.041M -6.667M

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013
Share price 5.33 5.28 1.88 2.68 6.75 24.21 0.41 2.27 1.9 1.9 15.51 10.4 —
Price performance 12m 0.01 1.82 -0.3 -0.6 -0.72 58.09 -0.82 0.2 -0 -0.88 0.49 — —

Filed figures

Figure Dec 2016 Dec 2017 Dec 2018 Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Borrowings, current (USD) — — — — 0.00 0.00 — — — —
Lease liabilities (USD) — — — — 1.09M 7.24M 6.38M 5.47M 4.48M 3.36M
Cash and deposits (USD) 36.4M 21.2M 19.4M 6.18M 169M 35.7M 24.1M 39.6M 163M 49.7M
Right-of-use assets (USD) — — — — 1.06M 7.17M 6.28M 5.26M 4.26M 3.17M
Net debt (borrowings + leases - cash) (USD) — — — — -168M -28.5M — — — —
Cash flow detail
Operating cash flow (USD) -23.7M -22.4M -23.2M -15.6M -23.4M -34.5M -26.5M -37.6M -35.8M -56.4M
Purchases of property, plant and equipment (USD) -271,000 -35,000 -119,000 -16,000 -884,000 -596,000 -120,000 -45,000 -63,000 -94,000
Change in payables (cash effect) (USD) 1.07M 4.16M -6.16M -2.5M 198,000 40,000 631,000 848,000 1.38M -873,000
Share buybacks (cash effect) (USD) — — — — — -228,000 -90,000 -91,000 — —
Interest paid (cash effect) (USD) — — — — -34,000 — — — — —
Share-based compensation (USD) 3.34M 3.23M 3.43M 943,000 9.75M 10.4M 6.69M 6.09M 4.13M 3.83M
Free cash flow (OCF - PPE - intangibles) (USD) -24M -22.4M -23.4M -15.7M -24.3M -35.1M -26.6M -37.6M -35.9M -56.5M
Income detail
Research and development expense (USD) 18.9M 21.7M 11.8M 6.44M 12M 21.1M 16.8M 25M 31.7M 42.6M
↳ 5y CAGR +29.7% +24.3% +0.0% -0.7% +2.2% -5.0% +16.1% +37.6% +28.9%
Total comprehensive income (USD) -28.5M -30M -20.7M -15M -34M -47.5M -66.4M -39.8M -44.6M -57.4M
Comprehensive income to owners (USD) -28.5M -30M -20.7M -15M -34M -47.5M -66.4M -39.8M -44.6M -57.4M
Reported Mar 16, 2017 Mar 14, 2018 Mar 13, 2019 Mar 20, 2020 Mar 9, 2022 Mar 9, 2022 Mar 8, 2023 Mar 13, 2024 Mar 5, 2025 Mar 10, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

Expect to complete enrollment of the BCG-Unresponsive registrational cohort of the ADVANCED-2 trial of TARA-002 in NMIBC by year-end 2026

Enrollment in registrational STARBORN-1 trial now expected to complete in early 1Q’2027; expect to initiate a rolling BLA submission for TARA-002 in LMs in 2H 2027

Completed enrollment of THRIVE-3 Phase 2b dosing cohort evaluating IV Choline Chloride in patients dependent on long-term parenteral support; remain on track to report interim results by year-end 2026

Entered into an asset purchase agreement with Novex Innovations for TARA-002 manufacturing-related assets for $8.75 million

Cash, cash equivalents and investments of approximately $143 million as of September 30, 2026, expected to support planned operations into 2028

NEW YORK, November 6, 2026 -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage biotechnology company developing transformative therapies for the treatment of cancer and rare diseases, today announced financial results for the third quarter ended September 30, 2026 and provided a business update.

October 15, 2026

Download PDF

Company remains on track to report interim results from Phase 2b cohort in 4Q 2026

NEW YORK, Oct. 15, 2026 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage biotechnology company developing transformative therapies for the treatment of cancer and rare diseases, today announced that it has completed enrollment of the Phase 2b, open-label dose confirmation phase of the THRIVE-3 clinical trial evaluating IV Choline Chloride in patients with intestinal failure who are dependent on parenteral support (PS). The dose confirmation phase of the trial includes 24 patients.

“We are excited about our progress in the registrational THRIVE-3 trial, which brings us one step closer to a solution for patients on parenteral support,” said Jesse Shefferman, Chief Executive Officer at Protara Therapeutics. “Choline plays a critical role in liver function, yet there are currently no approved PS formulations containing choline, leaving approximately 80 percent of the roughly 30,000 PS-dependent adult patients in the U.S. with choline deficiency. The majority of these patients suffer from some degree of liver damage. We believe IV Choline Chloride has the potential to become the first FDA-approved IV Choline formulation for PS patients. We look forward to reporting interim results from the Phase 2b dosing cohort of THRIVE-3 in the fourth quarter of this year.”

THRIVE-3 (NCT06910943) is a registrational, seamless Phase 2b/3 clinical trial evaluating the efficacy and safety of IV Choline Chloride in adolescent and adult patients with intestinal failure who are dependent on PS and have choline deficiency. The Phase 2b portion of the study is an open-label dose confirmation trial of 24 patients, designed to evaluate the safety and pharmacokinetics of IV Choline Chloride across multiple doses and to select dose(s) for continued evaluation. The Phase 3 trial is a randomized, double-blind, placebo-controlled phase of approximately 100 patients, designed to evaluate the efficacy of IV Choline Chloride in elevating plasma choline levels, as well as its safety. The primary endpoint is the change in plasma choline concentration from baseline to week 8 and the secondary endpoints include steatosis and liver function tests.

About IV Choline Chloride for Patients on Parenteral Support

IV Choline Chloride is an investigational, intravenous phospholipid substrate replacement therapy in development for patients receiving parenteral support (PS). Choline is an important substrate for phospholipids that are critical for healthy liver function and play an important role in modulating gene expression, cell membrane signaling, brain development and neurotransmission, muscle function and bone health. There are currently no available PS formulations containing choline. Every year in the U.S. there are approximately 90,000 people who require PS at home and of those approximately 30,000 are on long-term PS. IV Choline Chloride has the potential to become the first FDA approved IV choline formulation for PS patients. It has been granted Orphan Drug designation by the FDA for the prevention and/or treatment of choline deficiency in patients on long-term parenteral nutrition and has been granted Fast Track designation as a source of choline when oral or enteral nutrition is not possible, insufficient or contraindicated.

About Protara Therapeutics, Inc.

Protara is a clinical-stage biotechnology company committed to advancing transformative therapies for people with cancer and rare diseases. Protara’s portfolio includes its lead candidate, TARA-002, an investigational cell-based therapy in development for the treatment of non-muscle invasive bladder cancer (NMIBC) and lymphatic malformations (LMs). The Company is evaluating TARA-002 in ongoing clinical trials in NMIBC patients with carcinoma in situ (CIS) who are unresponsive or naïve to treatment with Bacillus Calmette-Guérin, as well as a pivotal Phase 2 trial in pediatric patients with LMs. Additionally, Protara is developing IV Choline Chloride, an investigational phospholipid substrate replacement for patients on parenteral support who are otherwise unable to meet their choline needs via oral or enteral routes. For more information, visit www.protaratx.com.

Forward-Looking Statements

Statements contained in this press release regarding matters that are not historical facts are “forward looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Protara may, in some cases, use terms such as “predicts,” “believes,” “potential,” “proposed,” “continue,” “designed,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should” or other words or expressions referencing future events, conditions or circumstances that convey uncertainty of future events or outcomes to identify these forward-looking statements. Such forward-looking statements include but are not limited to, statements regarding Protara’s intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things: Protara’s business strategy, including its development plans for its product candidates and plans regarding the timing or outcome of existing or future clinical trials (including the timing of any particular phases of such trials and the timing of the announcement of any data produced during such trials or phases thereof); statements related to expectations regarding interactions with the U.S. Food and Drug Administration (FDA); Protara’s financial position; statements regarding the anticipated safety or efficacy of Protara’s product candidates; and Protara’s outlook for the remainder of the year and future periods. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Factors that contribute to the uncertain nature of the forward-looking statements include: risks that Protara’s financial guidance may not be as expected, as well as risks and uncertainties associated with: Protara’s development programs, including the initiation and completion of non-clinical studies and clinical trials and the timing of required filings with the FDA and other regulatory agencies; general market conditions; changes in the competitive landscape; changes in Protara’s strategic and commercial plans; Protara’s ability to obtain sufficient financing to fund its strategic plans and commercialization efforts; having to use cash in ways or on timing other than expected; the impact of market volatility on cash reserves; failure to attract and retain management and key personnel; the impact of general U.S. and foreign, economic, industry, market, regulatory, political or public health conditions; and the risks and uncertainties associated with Protara’s business and financial condition in general, including the risks and uncertainties described more fully under the caption “Risk Factors” and elsewhere in Protara’s filings and reports with the United States Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made and are based on management’s assumptions and estimates as of such date. Protara undertakes no obligation to update any forward-looking statements, whether as a result of the receipt of new information, the occurrence of future events or otherwise, except as required by law.

Company Contact:

Justine O’Malley Protara Therapeutics [email protected] 646-817-2836

News Release image News Release image

News Release image

  • Print

Print

  • [Email Alerts

Email Alerts](https://ir.protaratx.com/email-alerts)

  • [RSS Feeds

RSS Feeds](https://ir.protaratx.com/rss-feeds)

  • Email Page

Email Page

Scroll to Top

September 8, 2026

Download PDF

NEW YORK, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc.(Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced that management will present at the H.C. Wainwright 28th Annual Global Investment Conference on Tuesday, September 15, 2026, at 2:00 pm ET.

A live webcast of the presentation can be accessed by visiting the Events and Presentations section of the Company’s website: https://ir.protaratx.com. The webcast will be archived for a limited time following the presentation.

About Protara Therapeutics, Inc.

Protara is a clinical-stage biotechnology company committed to advancing transformative therapies for people with cancer and rare diseases. Protara’s portfolio includes its lead candidate, TARA-002, an investigational cell-based therapy in development for the treatment of non-muscle invasive bladder cancer (NMIBC) and lymphatic malformations (LMs). The Company is evaluating TARA-002 in ongoing clinical trials in NMIBC patients with carcinoma in situ (CIS) who are unresponsive or naïve to treatment with Bacillus Calmette-Guérin, as well as a pivotal Phase 2 trial in pediatric patients with LMs. Additionally, Protara is developing IV Choline Chloride, an investigational phospholipid substrate replacement for patients on parenteral support who are otherwise unable to meet their choline needs via oral or enteral routes. For more information, visit www.protaratx.com.

Company Contact:

Justine O'Malley Protara Therapeutics [email protected] 646-817-2836

News Release image News Release image

News Release image

  • Print

Print

  • [Email Alerts

Email Alerts](https://ir.protaratx.com/email-alerts)

  • [RSS Feeds

RSS Feeds](https://ir.protaratx.com/rss-feeds)

  • Email Page

Email Page

Scroll to Top

Prompts

Protara Therapeutics, Inc. (ticker TARA), listed in United States.

Company History

Date Change Detail
May 13, 2020 Renamed ARTARA THERAPEUTICS, INC. → PROTARA THERAPEUTICS, INC.
Nov 29, 2019 Renamed PROTEON THERAPEUTICS INC → ARTARA THERAPEUTICS, INC.

ETFs Holding Protara Therapeutics, Inc.

ETF Weight in ETF Shares Market value As of
FEAC 0.04% 2,436 $ 9,305.52 Jun 30, 2026
AVSC 0.01% 94,616 $ 225.186K Nov 16, 2026
DFAS 0.00% 383,097 $ 934.757K Nov 12, 2026
DXUV 0.00% 25,134 $ 61.327K Nov 12, 2026
DFSU 0.00% 6,250 $ 15.25K Nov 12, 2026
DFAC 0.00% 14,686 $ 35.834K Nov 12, 2026
DCOR 0.00% 5,791 $ 14.13K Nov 12, 2026